Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy, Blindness, Eye disorder, Pyrexia
Clinical narrative: Fever; Permanent vision loss/ Permanent vision loss in the right eye; Another eye episode; This spontaneous case was reported by a consumer and describes the occurrence of BLINDNESS (Permanent vision loss/ Permanent vision loss in the right eye) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002B21A and 023M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included PANTOPRAZOLE, METOPROLOL SUCCINATE (TOPROL), AMLODIPINE and ALPRAZOLAM (ZOLAX [ALPRAZOLAM]) for an unknown indication.   On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Apr-2021, the patient experienced BLINDNESS (Permanent vision loss/ Permanent vision loss in the right eye) (seriousness criteria disability and medically significant) and EYE DISORDER (Another eye episode). On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, BLINDNESS (Permanent vision loss/ Permanent vision loss in the right eye) and EYE DISORDER (Another eye episode) had not resolved and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: normal (normal) Biopsy of artery leading to right eye.         Treatment provided included Prednisone.  After the second dose patient had an eye episode that did not go away after few minutes. It continued over the weekend and the patient visited a primary physician who was concerned about a stroke even though there were no stroke symptoms. From there patient was referred to cardiologist, rheumatologist and retinal specialist. Patient had shorter eye episode which began 22 days after the first vaccine and permanent vision loss began 20 days after the second dose. After six weeks of test and physician visits, a biopsy of the artery leading to right eye, the consulted cardiologist and found no problem in the heart, vascular specialist fount no issues in the arteries, rheumatologist found no systemic inflammation and autoimmune condition, Retinal specialist primarily provided treatment and did not diagnosed the cause but informed that the eye damage was not caused by a clot. There was no improvement in the vision and the retinal specialist was not optimistic that the vision will return.  Very limited information regarding the events has been provided at this time.  Further information has been requested.   This case was linked to (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-May-2021: Follow up was received on 20-May 2021 and updated  Patient demographics, concomitant  medications, batch number of vaccine, treatment medication.; Sender's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.